Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Pfizer awarded $1.35B Army contract modification for vaccine BNT162b2 production » 17:51
07/23/21
07/23
17:51
07/23/21
17:51
PFE

Pfizer

$41.69 /

+0.22 (+0.53%)

Pfizer was awarded a…

Pfizer was awarded a $1.35B modification to a contract for the production of vaccine BNT162b2. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of March 31, 2022. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
PFE Pfizer
$41.69 /

+0.22 (+0.53%)

PFE Pfizer
$41.69 /

+0.22 (+0.53%)

07/23/21 BMO Capital
Arvinas price target raised to $111 from $101 at BMO Capital
07/23/21 Citi
Arvinas price target raised to $153 from $118 at Citi
07/23/21 Oppenheimer
Arvinas price target raised to $108 from $100 at Oppenheimer
07/22/21 Roth Capital
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital
PFE Pfizer
$41.69 /

+0.22 (+0.53%)

PFE Pfizer
$41.69 /

+0.22 (+0.53%)

PFE Pfizer
$41.69 /

+0.22 (+0.53%)

PFE Pfizer
$41.69 /

+0.22 (+0.53%)

Hot Stocks
Glaxo begins shipping influenza vaccine supply for 2021-2022 U.S. season » 13:39
07/23/21
07/23
13:39
07/23/21
13:39
GSK

GlaxoSmithKline

$39.57 /

+0.32 (+0.82%)

GSK announced it started…

GSK announced it started shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2021-22 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration's Center for Biologics Evaluation and Research, the company said in a statement. GSK expects to distribute more doses than it has in any previous influenza season, with a record supply of more than 50 million doses of its influenza vaccine for the 2021-2022 season to the US market. "The flu remains a serious and unpredictable disease that can result in mild to severe illness. As more people are vaccinated against COVID-19 and we return to more normal, social activities, it is important that anyone over the age of 6 months is vaccinated against the flu," GSK said.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$39.57 /

+0.32 (+0.82%)

GSK GlaxoSmithKline
$39.57 /

+0.32 (+0.82%)

07/19/21 Barclays
GlaxoSmithKline price target raised to 1,300 GBp from 1,250 GBp at Barclays
07/06/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,590 GBp at Morgan Stanley
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
GSK GlaxoSmithKline
$39.57 /

+0.32 (+0.82%)

GSK GlaxoSmithKline
$39.57 /

+0.32 (+0.82%)

GSK GlaxoSmithKline
$39.57 /

+0.32 (+0.82%)

GSK GlaxoSmithKline
$39.57 /

+0.32 (+0.82%)

Hot Stocks
AbbVie announces FDA approval of Dalvance for bacterial skin infection » 12:52
07/23/21
07/23
12:52
07/23/21
12:52
ABBV

AbbVie

$118.46 /

+0.95 (+0.81%)

AbbVie announced that the…

AbbVie announced that the Food and Drug Administration approved Dalvance for the treatment of acute bacterial skin and skin structure infection in pediatric patients from birth. Dalvance is the first single-dose option administered as a 30-minute intravenous infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant staphylococcus aureus, the company said in a statement.

ShowHide Related Items >><<
ABBV AbbVie
$118.46 /

+0.95 (+0.81%)

ABBV AbbVie
$118.46 /

+0.95 (+0.81%)

07/02/21
Fly Intel: Top five analyst initiations
07/02/21 Daiwa
AbbVie initiated with an Outperform at Daiwa
06/30/21 Piper Sandler
Piper reiterates Overweight rating on Alpine following Merck collaboration
06/25/21 Piper Sandler
FDA won't meet PDUFA target dates for AbbVie's Rinvoq, says Piper Sandler
ABBV AbbVie
$118.46 /

+0.95 (+0.81%)

ABBV AbbVie
$118.46 /

+0.95 (+0.81%)

ABBV AbbVie
$118.46 /

+0.95 (+0.81%)

ABBV AbbVie
$118.46 /

+0.95 (+0.81%)

Recommendations
Arvinas price target raised to $111 from $101 at BMO Capital » 09:33
07/23/21
07/23
09:33
07/23/21
09:33
ARVN

Arvinas

$84.50 /

+6.9 (+8.89%)

, PFE

Pfizer

$41.48 /

+0.46 (+1.12%)

BMO Capital analyst…

BMO Capital analyst Matthew Luchini raised the firm's price target on Arvinas (ARVN) to $111 from $101 and keeps an Outperform rating on the shares. The analyst cites the company's global collaboration deal with Pfizer (PFE), which he calls a "solid partner" given its deep global development and commercialization expertise plus leading breast cancer franchise in Ibrance.

ShowHide Related Items >><<
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

07/23/21 Citi
Arvinas price target raised to $153 from $118 at Citi
07/23/21 H.C. Wainwright
Arvinas price target raised to $135 from $100 at H.C. Wainwright
07/23/21 Oppenheimer
Arvinas price target raised to $108 from $100 at Oppenheimer
07/22/21 Roth Capital
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

07/22/21 Piper Sandler
Arvinas price target raised to $105 from $97 at Piper Sandler
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

  • 16
    Dec
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

Hot Stocks
Pfizer, BioNTech to supply U.S. with additional 200M doses of Covid-19 vaccine » 06:46
07/23/21
07/23
06:46
07/23/21
06:46
PFE

Pfizer

$41.48 /

+0.46 (+1.12%)

, BNTX

BioNTech

$280.98 /

+21.26 (+8.19%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech SE (BNTX) announced that the U.S. government has purchased an additional 200M doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected to be delivered from October 2021 through April 2022. This brings the total number of doses to be supplied by the companies to the U.S. government under its existing supply agreement to 500M. In a separate announcement on June 10, 2021, Pfizer and BioNTech shared plans to provide the U.S. government with 500M doses of the companies' COVID-19 vaccine for donation to the world's poorest nations. The companies expect to deliver 110M of the additional doses by December 31, 2021, with the remaining 90M doses to be delivered no later than April 30, 2022. The U.S. government also has the option to acquire an updated version of the vaccine to address potential variants as well as new formulations of the vaccine, if available and authorized.

ShowHide Related Items >><<
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

07/23/21 Citi
Arvinas price target raised to $153 from $118 at Citi
07/23/21 Oppenheimer
Arvinas price target raised to $108 from $100 at Oppenheimer
07/22/21 Roth Capital
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital
07/22/21 Piper Sandler
Arvinas price target raised to $105 from $97 at Piper Sandler
BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

07/19/21 Wolfe Research
BioNTech assumed with an Outperform at Wolfe Research
06/16/21
Fly Intel: Top five analyst downgrades
06/16/21 Redburn
BioNTech downgraded to Sell from Neutral at Redburn
05/18/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

Recommendations
Arvinas price target raised to $153 from $118 at Citi » 06:26
07/23/21
07/23
06:26
07/23/21
06:26
ARVN

Arvinas

$84.50 /

+6.9 (+8.89%)

, PFE

Pfizer

$41.48 /

+0.46 (+1.12%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz raised the firm's price target on Arvinas (ARVN) to $153 from $118 and keeps a Buy rating on the shares. The Pfizer (PFE) deal is "transformational" for Arvinas as it lends validation to the PROTAC platform, substantially accelerates development efforts for ARV-471, and meaningfully strengthens the financial health of the company, Nochomovitz tells investors in a research note.

ShowHide Related Items >><<
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

07/23/21 H.C. Wainwright
Arvinas price target raised to $135 from $100 at H.C. Wainwright
07/23/21 Oppenheimer
Arvinas price target raised to $108 from $100 at Oppenheimer
07/22/21 Roth Capital
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital
07/22/21 Piper Sandler
Arvinas price target raised to $105 from $97 at Piper Sandler
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

07/22/21 Truist
Arvinas price target raised to $170 from $150 at Truist
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

  • 16
    Dec
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

Periodicals
Vaccine panel expresses preliminary support for Covid boosters, WSJ reports » 06:08
07/23/21
07/23
06:08
07/23/21
06:08
JNJ

Johnson & Johnson

$170.00 /

+0.5 (+0.29%)

, PFE

Pfizer

$41.48 /

+0.46 (+1.12%)

, BNTX

BioNTech

$280.98 /

+21.26 (+8.19%)

, MRNA

Moderna

$323.46 /

+2.53 (+0.79%)

The Advisory Committee on…

The Advisory Committee on Immunization Practices panel, A U.S. advisory panel on vaccines which advises the U.S. Centers for Disease Control and Prevention, expressed preliminary support for giving Covid-19 boosters to the immunocompromised, and endorsed continued use of the Johnson & Johnson vaccine despite a recent health-risk warning, The Wall Street Journal's Jared S. Hopkins and Felicia Schwartz report. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

MRNA Moderna
$323.46 /

+2.53 (+0.79%)

JNJ Johnson & Johnson
$170.00 /

+0.5 (+0.29%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

JNJ Johnson & Johnson
$170.00 /

+0.5 (+0.29%)

07/08/21 Stifel
Vor Biopharma, Janssen collaboration benefits both parties, says Stifel
07/02/21 Cantor Fitzgerald
J&J vaccine shows 'strong' activist against Delta, says Cantor Fitzgerald
06/28/21 Cantor Fitzgerald
J&J opioid settlement removes share overhang, says Cantor Fitzgerald
06/22/21 JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

07/23/21 Oppenheimer
Arvinas price target raised to $108 from $100 at Oppenheimer
07/22/21 Roth Capital
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital
07/22/21 Piper Sandler
Arvinas price target raised to $105 from $97 at Piper Sandler
07/22/21 Truist
Arvinas price target raised to $170 from $150 at Truist
BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

07/19/21 Wolfe Research
BioNTech assumed with an Outperform at Wolfe Research
06/16/21
Fly Intel: Top five analyst downgrades
06/16/21 Redburn
BioNTech downgraded to Sell from Neutral at Redburn
05/18/21
Fly Intel: Top five analyst initiations
MRNA Moderna
$323.46 /

+2.53 (+0.79%)

07/15/21 Jefferies
Moderna price target raised to $250 from $170 at Jefferies
07/07/21 Piper Sandler
Moderna could 'revolutionize' flu vaccine market, says Piper Sandler
06/29/21 Wells Fargo
Moderna vaccine demonstrates activity against key variants, says Wells Fargo
06/29/21 Goldman Sachs
Goldman continues to anticipate clinical need for booster vaccines
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

MRNA Moderna
$323.46 /

+2.53 (+0.79%)

JNJ Johnson & Johnson
$170.00 /

+0.5 (+0.29%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

MRNA Moderna
$323.46 /

+2.53 (+0.79%)

JNJ Johnson & Johnson
$170.00 /

+0.5 (+0.29%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

MRNA Moderna
$323.46 /

+2.53 (+0.79%)

JNJ Johnson & Johnson
$170.00 /

+0.5 (+0.29%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

MRNA Moderna
$323.46 /

+2.53 (+0.79%)

JNJ Johnson & Johnson
$170.00 /

+0.5 (+0.29%)

BNTX BioNTech
$280.98 /

+21.26 (+8.19%)

Recommendations
Arvinas price target raised to $108 from $100 at Oppenheimer » 04:54
07/23/21
07/23
04:54
07/23/21
04:54
ARVN

Arvinas

$84.50 /

+6.9 (+8.89%)

, PFE

Pfizer

$41.48 /

+0.46 (+1.12%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach raised the firm's price target on Arvinas (ARVN) to $108 from $100 and reiterates an Outperform rating on the shares after the company and Pfizer (PFE) announced a global collaboration to accelerate development and commercialization of ARV-471. The analyst believes non-public clinical data "may have helped entice" Pfizer, which he sees as an "ideal partner with a well-established commercial footprint in the breast cancer space."

ShowHide Related Items >><<
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

07/22/21 Roth Capital
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital
07/22/21 Piper Sandler
Arvinas price target raised to $105 from $97 at Piper Sandler
07/22/21 Truist
Arvinas price target raised to $170 from $150 at Truist
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

07/20/21 Lake Street
Achieve Life weakness on Chantix news would be opportunity, says Lake Street
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

ARVN Arvinas
$84.50 /

+6.9 (+8.89%)

  • 16
    Dec
PFE Pfizer
$41.48 /

+0.46 (+1.12%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

PFE Pfizer
$41.48 /

+0.46 (+1.12%)

Thursday
Initiation
Siemens Healthineers initiated with a Buy at Societe Generale » 18:16
07/22/21
07/22
18:16
07/22/21
18:16
SMMNY

Siemens Healthineers

$32.25 /

+0.56 (+1.77%)

Societe Generale analyst…

Societe Generale analyst Delphine Le Louet initiated coverage of Siemens Healthineers with a Buy rating and EUR 61.70 price target. The analyst said that the Buy rating is underpinned by the company's structurally growing end-markets; the innovation driving its growth in an expanding market; its market leading positions and potential for margin improvement; and the Varian integration.

ShowHide Related Items >><<
SMMNY Siemens Healthineers
$32.25 /

+0.56 (+1.77%)

SMMNY Siemens Healthineers
$32.25 /

+0.56 (+1.77%)

07/15/21 Barclays
Siemens Healthineers price target raised to EUR 49 from EUR 47 at Barclays
06/14/21 UBS
Siemens Healthineers price target raised to EUR 48 from EUR 46 at UBS
05/04/21 JPMorgan
Siemens Healthineers price target lowered to EUR 54.40 at JPMorgan
05/04/21 Credit Suisse
Siemens Healthineers price target raised to EUR 55 from EUR 54 at Credit Suisse
SMMNY Siemens Healthineers
$32.25 /

+0.56 (+1.77%)

SMMNY Siemens Healthineers
$32.25 /

+0.56 (+1.77%)

Recommendations
Pfizer investment in Arvinas shows 'growing confidence,' says Roth Capital » 12:52
07/22/21
07/22
12:52
07/22/21
12:52
ARVN

Arvinas

$85.18 /

+7.575 (+9.76%)

, PFE

Pfizer

$41.25 /

+0.23 (+0.56%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Arvinas (ARVN) with a $120 price target after the company announced a development and collaboration agreement with Pfizer (PFE) for ARV-471. The agreement "appears more substantial" than the original 2018 discovery and development agreement between Arvinas and Pfizer, Jallah tells investors in a research note. The analyst views the new agreement, which includes a $650M upfront payment for exclusive rights to a single early-stage asset, as "perhaps strong validation of the derisking of the platform that has occurred." Additionally, Pfizer's investment of $350M for a 7% equity stake, at a 30% premium, is further evidence of its "growing confidence in the platform," says Jallah, who "would not be surprised to see a broadening of this partnership."

ShowHide Related Items >><<
PFE Pfizer
$41.25 /

+0.23 (+0.56%)

ARVN Arvinas
$85.18 /

+7.575 (+9.76%)

ARVN Arvinas
$85.18 /

+7.575 (+9.76%)

07/22/21 Piper Sandler
Arvinas price target raised to $105 from $97 at Piper Sandler
07/22/21 Truist
Arvinas price target raised to $170 from $150 at Truist
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
05/20/21 UBS
Arvinas initiated with a Buy at UBS
PFE Pfizer
$41.25 /

+0.23 (+0.56%)

07/20/21 Lake Street
Achieve Life weakness on Chantix news would be opportunity, says Lake Street
07/06/21 Lake Street
Achieve Life Sciences weakness a buying opportunity, says Lake Street
PFE Pfizer
$41.25 /

+0.23 (+0.56%)

ARVN Arvinas
$85.18 /

+7.575 (+9.76%)

  • 16
    Dec
PFE Pfizer
$41.25 /

+0.23 (+0.56%)

PFE Pfizer
$41.25 /

+0.23 (+0.56%)

PFE Pfizer
$41.25 /

+0.23 (+0.56%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.